Astria Therapeutics Stock Skyrockets 53% After $700M Buyout – What’s Next?
On Oct. 14, 2025, Astria was swept into the headlines by a surprise $700+ million takeover. BioCryst Pharmaceuticals announced a definitive merger agreement to acquire Astria for $8.55 in cash plus 0.59 shares of BioCryst stock per Astria share marketscreener.com reuters.com. This values Astria at roughly $920M equity and $700M enterprise stocktitan.net. The Boards of both companies approved the deal, which is expected to close in Q1 2026 stocktitan.net. Astria CEO Jill Milne will join BioCryst’s board post-merger stocktitan.net.
